Andrew Walding

1.5k total citations
32 papers, 1.1k citations indexed

About

Andrew Walding is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Andrew Walding has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Andrew Walding's work include Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (9 papers) and Advanced Breast Cancer Therapies (7 papers). Andrew Walding is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Colorectal Cancer Treatments and Studies (9 papers) and Advanced Breast Cancer Therapies (7 papers). Andrew Walding collaborates with scholars based in United Kingdom, United States and Japan. Andrew Walding's co-authors include David L. Laughton, Adrian J. Wolstenholme, Sabina Alam, Myung‐Ju Ahn, Sundar Ramalingam, Seung‐Whan Kim, Geoffrey R. Oxnard, James Chih‐Hsin Yang, Helena A. Yu and Kōichi Goto and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Andrew Walding

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Walding United Kingdom 15 673 567 250 133 110 32 1.1k
Zofia E. Dziewanowska United States 14 390 0.6× 436 0.8× 499 2.0× 102 0.8× 80 0.7× 25 1.2k
L.L. Miller United States 13 229 0.3× 332 0.6× 335 1.3× 220 1.7× 70 0.6× 30 900
Michele Zorzetto Italy 22 675 1.0× 327 0.6× 345 1.4× 151 1.1× 367 3.3× 60 1.5k
Jon Lømo Norway 19 213 0.3× 319 0.6× 481 1.9× 266 2.0× 224 2.0× 38 1.1k
Min Feng China 18 126 0.2× 240 0.4× 251 1.0× 177 1.3× 140 1.3× 31 803
Torsten Dunkern Germany 17 205 0.3× 181 0.3× 625 2.5× 78 0.6× 122 1.1× 23 954
Jean–Louis Formento France 21 372 0.6× 846 1.5× 371 1.5× 45 0.3× 159 1.4× 35 1.3k
Jeong‐Hun Ko United Kingdom 14 157 0.2× 131 0.2× 467 1.9× 189 1.4× 100 0.9× 23 781
Eiji Takai Japan 17 282 0.4× 209 0.4× 225 0.9× 74 0.6× 140 1.3× 36 843

Countries citing papers authored by Andrew Walding

Since Specialization
Citations

This map shows the geographic impact of Andrew Walding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Walding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Walding more than expected).

Fields of papers citing papers by Andrew Walding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Walding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Walding. The network helps show where Andrew Walding may publish in the future.

Co-authorship network of co-authors of Andrew Walding

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Walding. A scholar is included among the top collaborators of Andrew Walding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Walding. Andrew Walding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamilton, Erika, S. Loibl, Thomas Bachelot, et al.. (2025). CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer. Future Oncology. 21(7). 795–806. 1 indexed citations
2.
3.
Ahn, Myung‐Ju, Byoung Chul Cho, Xiaoling Ou, et al.. (2022). Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. Journal of Thoracic Oncology. 17(5). 718–723. 50 indexed citations
4.
Walding, Andrew, et al.. (2022). Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions. Quality of Life Research. 31(8). 2535–2543. 3 indexed citations
5.
Cheng, Ying, Yong He, Wěi Li, et al.. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology. 16(2). 165–176. 90 indexed citations
6.
Martin, Mona L., et al.. (2021). How patients being treated for non-small cell lung cancer value treatment benefit despite side effects. Quality of Life Research. 31(1). 135–146. 3 indexed citations
7.
Tsuboi, Masahiro, Walter Weder, Carles Escriu, et al.. (2021). Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA. Future Oncology. 17(31). 4045–4055. 106 indexed citations
8.
9.
Leighl, Natasha B., Nina Karaseva, Kazuhiko Nakagawa, et al.. (2019). Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. European Journal of Cancer. 125. 49–57. 46 indexed citations
10.
11.
Zhou, Chao, Ying Cheng, Yong He, et al.. (2018). P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S507–S508. 3 indexed citations
12.
Sebastian, Martin, Anna Rydén, Andrew Walding, & Vassiliki A. Papadimitrakopoulou. (2018). Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 122. 100–106. 11 indexed citations
13.
Rydén, Anna, Fiona Blackhall, Hye Ryun Kim, et al.. (2017). Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. Patient. 10(5). 593–603. 9 indexed citations
14.
Ahn, Myung‐Ju, James Chih‐Hsin Yang, Helena A. Yu, et al.. (2016). 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. Journal of Thoracic Oncology. 11(4). S115–S115. 194 indexed citations
15.
Luckhurst, Christopher A., M. Ratcliffe, Mark Furber, et al.. (2010). Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists. Bioorganic & Medicinal Chemistry Letters. 21(1). 531–536. 10 indexed citations
16.
Luckhurst, Christopher A., Mark Furber, M. Ratcliffe, et al.. (2010). Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists. Bioorganic & Medicinal Chemistry Letters. 21(1). 492–496. 25 indexed citations
17.
Doyle, Ian, M. Ratcliffe, Andrew Walding, et al.. (2009). Differential gene expression analysis in human monocyte-derived macrophages: Impact of cigarette smoke on host defence. Molecular Immunology. 47(5). 1058–1065. 28 indexed citations
18.
Scott, Ian C., Anita Midha, Umer Rashid, et al.. (2008). Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1β-driven model of joint pathology. Osteoarthritis and Cartilage. 17(6). 790–797. 19 indexed citations
19.
Alam, Sabina, David L. Laughton, Andrew Walding, & Adrian J. Wolstenholme. (2005). Human peripheral blood mononuclear cells express GABAA receptor subunits. Molecular Immunology. 43(9). 1432–1442. 129 indexed citations
20.
Litjens, Nicolle H. R., Mirjam Rademaker, Bep Ravensbergen, et al.. (2004). Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses. European Journal of Immunology. 34(2). 565–575. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zofia E. Dziewanowska Breakdown of academic impact, for papers by L.L. Miller Breakdown of academic impact, for papers by Michele Zorzetto Breakdown of academic impact, for papers by Jon Lømo Breakdown of academic impact, for papers by Min Feng Breakdown of academic impact, for papers by Torsten Dunkern Breakdown of academic impact, for papers by Jean–Louis Formento Breakdown of academic impact, for papers by Jeong‐Hun Ko Breakdown of academic impact, for papers by Eiji Takai
Rankless by CCL
2026